Chemotherapy cost: what Medicare pays and what patients owe

Chemotherapy cost depends on the regimen, the number of cycles, the site of care, and your insurance plan. This guide uses 2023 CMS Medicare spending data to show what the federal government actually pays for cancer drug therapy, what Medicare patients owe in coinsurance, and how commercial insurance compares.

Medicare spending by drug

The table below shows 2023 average annual Medicare spending per beneficiary for 15 commonly prescribed cancer drugs. Figures come directly from the CMS Medicare Part B and Part D Spending by Drug datasets.

Source: CMS Medicare Part B Spending by Drug and Medicare Part D Spending by Drug, data year 2023.

Medicare spending per beneficiary is not what you pay. It is the gross program cost. Under Original Medicare, beneficiaries are typically responsible for 20 percent of the Part B allowed amount. Medigap plans generally cover that 20 percent. Medicare Advantage plans cap annual in-network out-of-pocket spending at $8,850 (2024). Commercial insurance cost-sharing varies by plan and drug tier.

What drives the cost

Four factors set the bill:

1. Drug choice. Pembrolizumab (Keytruda) costs orders of magnitude more than an older cytotoxic like cyclophosphamide. Clinical guidelines often recommend the newer drugs where outcome data supports them.
2. Number of cycles. A 12-cycle regimen costs twice what a 6-cycle regimen does. For metastatic disease, some patients remain on therapy indefinitely.
3. Site of care. Hospital outpatient departments are typically reimbursed at higher rates than freestanding oncology clinics for the same drug. This is called site-of-service differential pricing.
4. Weight and dosing. Many drugs are dosed by body weight (mg/kg) or body surface area. Larger patients receive more drug per cycle.

Insurance coverage breakdown

Medicare

Part B (outpatient and infusion). Covers drugs administered in a clinic or hospital, including Keytruda, Opdivo, Herceptin, and Perjeta. Medicare reimburses at Average Sales Price (ASP) plus 6 percent. The beneficiary is responsible for 20 percent coinsurance unless a Medigap supplement covers it.

Part D (oral and pharmacy). Covers pills filled at a retail or specialty pharmacy, including Ibrance, Verzenio, Xtandi, Tagrisso, and Lynparza. Copay depends on the Part D plan and formulary tier. Specialty cancer drugs almost always land in the highest tier.

Medicare Advantage. Caps annual in-network out-of-pocket spending at $8,850 for 2024. This cap is a significant protection for patients on expensive regimens.

Extra Help. Low-income Medicare beneficiaries may apply for the Extra Help program, which caps Part D copays at a few dollars per prescription. Applications go through SSA.gov.

Commercial insurance

Typical structure:

• Deductible (paid first, before insurance contributes)
• Coinsurance (percentage of cost after deductible, often 20-30%)
• Copay (flat amount per fill, for tiered drug formularies)
• Out-of-pocket maximum (annual cap; $9,450 individual / $18,900 family for 2024 ACA plans)

Specialty drugs almost always land in the highest formulary tier with the highest coinsurance. Many plans require prior authorization and step therapy (trying cheaper drugs first) before approving expensive ones.

Uninsured

Every brand-name oncology drug has a manufacturer patient assistance program. Most provide the drug at no cost to income-eligible uninsured patients. Income limits typically sit around 400 to 500 percent of the federal poverty level, patients must be U.S. residents, and applicants cannot have other insurance covering the drug. Program details and contact information are linked from each drug cost page and on NeedyMeds.

Nonprofit hospitals are legally required to offer financial assistance (often called charity care) to patients unable to pay. Ask the cancer center’s financial counselor to apply.

Cycles, regimens, and how to read your bill

Chemotherapy is given in cycles, typically every two to four weeks. A regimen specifies the drugs and the cycle length. Examples:

• AC-T (breast cancer adjuvant). Four cycles of AC (doxorubicin and cyclophosphamide) every three weeks, then four cycles of paclitaxel every three weeks. Total length is roughly six months.
• FOLFOX (colorectal). Every two weeks, usually for 12 cycles. Total length is roughly six months.
• FOLFIRINOX (pancreatic). Every two weeks, continued until disease progression.
• R-CHOP (diffuse large B-cell lymphoma). Every three weeks for six cycles. Total length is roughly four months.
• Pembrolizumab monotherapy (various cancers). Every three to six weeks, continued until progression or for up to two years.

A typical infusion visit bill includes:

• The drugs, billed under HCPCS J-codes (for example, J9271 is pembrolizumab)
• Infusion administration (CPT 96413 for the first hour, 96415 for each additional hour, 96417 for each additional drug)
• Pre-medications such as anti-nausea drugs and steroids
• Port flushes and access fees if you have a central venous port
• Associated laboratory work (CBC, CMP, tumor markers)
• A physician evaluation visit

Medicare reimburses infusion administration codes (96413 / 96415) in the range of roughly $100 to $250 per hour. Commercial insurance typically pays more. The drug itself is usually the largest single line item on the bill.

How to reduce what you pay

1. Meet with a financial counselor on day one. Every accredited cancer center has one. They know which programs are currently open for funding and which your diagnosis qualifies for.
2. Apply to the manufacturer patient assistance program. Every brand-name oncology drug has one. The specific program is linked from each drug cost page.
3. Apply to disease-foundation copay funds. HealthWell, PAN Foundation, CancerCare, and Blood Cancer United (formerly the Leukemia & Lymphoma Society) maintain active funds for most cancer types. See the financial assistance guide.
4. Compare site-of-care options. Some commercial plans negotiate lower rates at freestanding oncology clinics than at hospital outpatient departments. Ask your plan for a cost estimate at each.
5. Appeal prior-authorization denials. Most appealed denials are overturned on internal or external review.
6. Consider enrollment in a clinical trial. Trials frequently cover the cost of the investigational drug. See how to find a clinical trial.
7. Ask about biosimilars. For drugs like trastuzumab (Herceptin) and bevacizumab (Avastin), FDA-approved biosimilars are typically 20 to 30 percent less expensive than the reference product and have clinical equivalence demonstrated for their indicated uses.

Cost by cancer type

Each cancer hub on this site links to the FDA-approved drugs for that cancer, along with their Medicare spending figures where available. Start at the cancers index and click through to your diagnosis.

What this guide does not tell you

It does not tell you what your personal bill will be. That depends on your specific insurance plan, your regimen, your body weight, the state you live in, and your provider’s negotiated rates. The figures above are federal-data benchmarks. Your actual liability is determined by factors only your insurer and provider can quote.

Before starting treatment, ask your insurance:

• Is this drug covered under my plan?
• What formulary tier is it on?
• What are my coinsurance and copay amounts?
• Does this regimen require prior authorization or step therapy?
• What is my annual out-of-pocket maximum and how much have I met already?

Next

• Financial assistance for cancer patients: the complete list of programs
• Drug costs overview: Medicare spending data for 15 oncology drugs
• Insurance coverage for clinical trials: ACA requirements
• Questions to ask your oncologist